Compare HP Inc (HPQ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs BIO-TECHNE Corp — how do they compare? HP Inc trades at $30.33 (market cap $29.25B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: HP Inc is far larger — about 2.6× BIO-TECHNE Corp's market cap, and HP Inc pays the higher dividend (3.7%). Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and BIO-TECHNE Corp for 63 Days on average.
| HPQ | TECH | |
|---|---|---|
Market Cap | $29.25B | $11.36B |
Volume | 10,025,806 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $35.48 | $72.61 |
52-Week Low | $18.20 | $43.31 |
Typical Hold Time | 70 Days | 63 Days |
Enterprise Value | $35.42B | $11.39B |
Dividend Yield | 3.7% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ is trading at $30.37, down 5.8% over the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $55.30 billion in 2025 and has beaten earnings estimates for the last three quarters. Recent news highlights HP's new product launches and a dividend payment scheduled for October 2026, though the stock faces pressure from a forecasted decline in PC sales for 2027.
The outlook for HPQ is mixed, with strong cash flow and consistent earnings beats providing support, but risks from a weakening PC market and high liabilities tempering upside. Analyst consensus is a hold with a price target of $25.75, suggesting cautious optimism amid industry headwinds. Investment opportunity lies in valuation metrics like a low P/E of 12.38, but execution risks remain key.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
